文献速递免疫规划

6-7岁儿童加强免疫接种两种气溶胶或注射麻腮风疫苗一年后抗体持久性

Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
PubMed 文献 · Vaccine · 2017-04-28

本研究对既往随机分组接种麻腮风疫苗(气溶胶或注射途径,SII或MMR II)的6-7岁墨西哥儿童进行一年随访,241/260人完成。免疫后一年,所有组麻疹和风疹血清阳性率均为100%,腮腺炎血清阳性率90.3%至96.6%组间无统计学显著差异;除气溶胶SII组麻疹GMT外,各组三种病毒GMT均下降;仅见轻度临床事件。

要点

  • 免疫后一年所有组麻疹和风疹血清阳性率均为100%。
  • 腮腺炎血清阳性率从注射MMR II组的90.3%至气溶胶MMR SII组的96.6%,差异无统计学显著。
  • 除气溶胶MMR SII组麻疹GMT外,各组三种病毒GMT均下降;气溶胶MMR SII与MMR II组腮腺炎抗体差异有统计学显著。

核心结论

  • 在麻疹和风疹无地方性传播、腮腺炎病毒低流行的条件下,学龄儿童加强免疫一年后对三种病毒仍保持血清阳性。

研究设计与样本

  • 对既往随机分组接种麻腮风疫苗的6-7岁墨西哥儿童进行临床和血清学随访,初始260人,241人完成一年随访。
  • 参与者随机分四组,分别经气溶胶或注射途径接种MMR SII(印度血清研究所)或MMR II(默沙东)。
  • 通过斑块减少中和试验检测麻疹抗体,通过ELISA检测风疹和腮腺炎抗体;护士团队定期到学校和家庭访视评估临床事件。

主要发现

  • 免疫后一年,所有组麻疹和风疹血清阳性率均为100%。
  • 腮腺炎血清阳性率从注射MMR II组的90.3%至气溶胶MMR SII组的96.6%,差异无统计学显著。
  • 除气溶胶MMR SII组麻疹GMT外,所有研究组三种病毒的GMT均下降。
  • 气溶胶MMR SII与MMR II组间腮腺炎抗体差异有统计学显著。
  • 仅发现轻度临床事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In a previous study on booster vaccination, we reported that two aerosolized MMR vaccines were as safe and immunogenic as injectable vaccines containing the same antigens. We now present results of antibody persistence one year after immunization. OBJECTIVE: To assess the antibody persistence for measles, mumps, and rubella one year following booster immunization. METHODS: We performed clinical and serological follow-up of participants in a previous study of Mexican children aged 6-7years, in which participants were randomized to four groups receiving, by aerosolized or by injection, the MMR SII vaccine (Serum Institute of India), or the MMR II (Merck Sharp & Dhome). We evaluated the antibody persistence by PRN test for measles and by ELISA for rubella and mumps. The occurrence of clinical events was evaluated via periodic visits of a nurse team to children's schools and homes. RESULTS: Of the 260 initial participants, 241 completed one-year follow-up. There were only statistically significant differences in baseline seropositivity for mumps. One year after immunization, seropositivity in all groups was 100% for measles and rubella. The seropositivity rank for mumps was from 90.3% for the injected vaccine MMR II to 96.6% for vaccine MMR SII applied by aerosol; these differences were not statistically significant. With exception of the aerosolized vaccine MMR SII for the geometric mean titer (GMT) for measles, all study groups presented declination of GMT for the three viruses. The difference between the aerosolized vaccines MMR SII and MMR RII was statistically significant for mumps antibodies. Only mild clinical events were identified. CONCLUSION: Under conditions of no endemic transmission for measles and rubella, and of low circulation of mumps virus, school-aged children remained seropositive to the three viruses one year following booster immunization. The study was registered under CMN 2010-005 number at COFEPRIS (National Regulatory Authority).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, et al. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Vaccine. 2017. PMID: 28457672. doi:10.1016/j.vaccine.2017.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。